Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-05-01 Major Shareholding Noti…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 10 pages 142.7KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Form 605 Notice of ceasing to be a substantial holder' under the Corporations Act 2001, Section 671B. It details changes in relevant interests of a substantial holder, including dates, nature of changes, and securities affected. It also includes prescribed information about securities lending agreements and voting rights restrictions. The document is regulatory in nature, reporting changes in substantial shareholdings and related agreements. It does not contain financial statements, earnings data, or management commentary. It is a formal notification of changes in substantial shareholding status, which aligns with the category 'Major Shareholding Notification' (MRQ). The document length is over 11,000 characters, indicating it is a full notice rather than a brief announcement. Therefore, the correct classification is MRQ with high confidence.
2022-05-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 419.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C QUARTERLY ACTIVITY REPORT' and provides detailed operational and financial highlights for the quarter ended March 31, 2022. It includes substantive financial data such as net cash usage, revenues, cash on hand, and detailed updates on clinical trials and regulatory interactions. The document also mentions executive appointments and includes a quarterly cash flow report (Appendix 4C) as an attachment. The length of the document (15,000 characters) and the presence of detailed financial and operational data indicate this is a comprehensive quarterly report rather than a brief announcement or certification. The quarterly period and detailed financial and operational information align with the definition of an Interim / Quarterly Report (IR).
2022-04-28 English
6-K
Regulatory Filings
2022-04-20 English
Becoming a substantial holder 29 pages 1.3MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act 2001 Section 671B, which pertains to the notice of an initial substantial holder. The content details the substantial shareholding of JPMorgan Chase & Co. and its affiliates in Mesoblast Ltd, including voting power, relevant interests, registered holders, consideration paid, and associates. The document includes detailed tables of share transactions and holdings. This type of filing is a notification of a major shareholding interest, specifically reporting when a party becomes a substantial holder in a company, as required by Australian securities regulations. It is not a financial report, earnings release, or management information, but a regulatory notification about share ownership levels crossing thresholds. Therefore, the appropriate classification is 'Major Shareholding Notification' (MRQ). The document length and detail support a high confidence in this classification.
2022-04-18 English
Appendix 3G and Appendix 3H 21 pages 399.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form filed with the ASX, which is a notification of the issue, conversion, or payment up of unquoted equity securities. It is a regulatory announcement about securities issued under an employee incentive scheme that are not intended to be quoted on ASX. The document is a formal notification of capital changes related to securities issuance and conversions, not a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital structure changes. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2022-04-13 English
6-K
Regulatory Filings
2022-04-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.